Novel Sulfide Releasing Agents for Ischemic Injury
Novel Sulfide Releasing Agents for Ischemic Injury
批准号:
8629076
负责人:
DAVID JOSEPH LEFER
金额:
$38.86万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-02-17 至 2018-01-31
关键词:
AcuteAcute myocardial infarctionAddressAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApoptoticBiologicalBiological ModelsBiologyBiomedical ResearchCarbon MonoxideCardiacCationsCellsChemical AgentsChemistryChronicClinicalDataDendrimersDetectionDevelopmentDiseaseDown-RegulationDrug KineticsExhibitsFutureGenerationsGoalsHeart failureHydrogen SulfideHypoxiaIn VitroInfarctionInjuryInvestigationLeadLeft Ventricular FunctionLifeLightMeasuresMetabolismMethodsMitochondriaModelingModificationMonitorMusMuscle CellsMyocardial IschemiaMyocardiumNitric OxideOxidative StressOxygen ConsumptionPharmacologyPhysiologyProblem SolvingProductionReperfusion InjuryReperfusion TherapyResearchResearch PersonnelRespirationSeriesSignaling MoleculeSolidStructure-Activity RelationshipSulfhydryl CompoundsSulfidesTestingTherapeuticTimeVasodilationbasecytotoxicitydesigndithioldrug developmentimprovedin vivoin vivo Modelnovelphosphorodithioic acidprotective effectpublic health relevanceresearch studytool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Hydrogen sulfide (H2S) is a newly recognized signaling molecule with very potent
cytoprotective actions. The fields of H2S physiology and pharmacology have been rapidly growing in
recent years, but a number of fundamental issues must be addressed to advance our understanding
of the biology and clinical potential of H2S in the future. It is important to study the chemistry and
pharmacology of exogenous H2S, to be aware of the limitations associated with the choice of chemical
agents used to generate H2S in vitro and in vivo. In this regard, synthetic H2S-releasing agents (i.e.
H2S donors) are important research tools and potentially very valuable therapeutic candidates for drug
development. However, currently available H2S donors are very limited in terms of research use or
clinical development since those compounds are very short-lived and the timing and amount of H2S
release is largely uncontrollable. To solve these problems, we have recently developed four types of
new H2S donors based on N-mercapto, perthiol, gem-dithiol, and phosphorodithioate templates. H2S
generations from these donors can be controlled by different mechanisms and the rates of H2S
generation can be regulated upon structural modifications. We also found that the administration of
H2S donors at the time of reperfusion significantly decreased infarct size and preserved left ventricular
function in an in vivo murine model of myocardial ischemia/reperfusion injury. In this project, we plan
to develop a toolbox of long-lasting and controllable H2S releasing agents and apply them to explore
the pharmacology of H2S under pathological disease states in in vitro and in vivo model systems.
Three Specific Aims will be pursued: 1) to design, synthesize, and evaluate controllable H2S donors,
2) to screen the activities of synthetic H2S donors under in vitro conditions; and 3) to examine the
cardioprotective actions of donors in acute myocardial ischemia/reperfusion (MI/R) injury and chronic
heart failure. We believe that the proposed research will expand our understanding of the
chemistry/pharmacology of H2S and provide valuable tools and information to facilitate H2S
biomedical research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hydrogen Sulfide Regulation in Cardioprotection
-
批准号:10391506
-
项目类别:
-
资助金额:$56.2万
-
财政年份:2020
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Hydrogen Sulfide Regulation in Cardioprotection
-
批准号:10162413
-
项目类别:
-
资助金额:$57.6万
-
财政年份:2020
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Hydrogen Sulfide Regulation in Cardioprotection
-
批准号:10610727
-
项目类别:
-
资助金额:$54.7万
-
财政年份:2020
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Endogenous Hydrogen Sulfide Enzymes in Heart Failure
-
批准号:10077584
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2019
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Novel Mitochondrial DNA Repair Enzyme for Heart Failure
-
批准号:9408031
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2017
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Novel antifibrotic small molecules for the treatment of heart failure
-
批准号:9142025
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2016
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Novel Sulfide Releasing Agents for Ischemic Injury
-
批准号:8889814
-
项目类别:
-
资助金额:$3.11万
-
财政年份:2014
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Nitrite Mediated Cardioprotection
-
批准号:8289582
-
项目类别:
-
资助金额:$25.42万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Nitrite Mediated Cardioprotection
-
批准号:7900081
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Nitrite Mediated Cardioprotection
-
批准号:8835549
-
项目类别:
-
资助金额:$12.94万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Cardioprotective Actions of Hydrogen Sulfide
-
批准号:8399050
-
项目类别:
-
资助金额:$8.06万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Cardioprotective Actions of Hydrogen Sulfide
-
批准号:7754425
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Cardioprotective Actions of Hydrogen Sulfide
-
批准号:8921357
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Nitrite Mediated Cardioprotection
-
批准号:8085943
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Cardioprotective Actions of Hydrogen Sulfide
-
批准号:8207216
-
项目类别:
-
资助金额:$38.36万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Nitrite Mediated Cardioprotection
-
批准号:7742542
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Cardioprotective Actions of Hydrogen Sulfide
-
批准号:7599368
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Cardioprotective Actions of Hydrogen Sulfide
-
批准号:8011098
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
MECHANISMS OF MYOCARDIAL REPERFUSION INJURY--DIABETES
-
批准号:6184820
-
项目类别:
-
资助金额:$17.7万
-
财政年份:1999
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
Mechanism of Myocardial Reperfusion Injury in Diabetes
-
批准号:6998480
-
项目类别:
-
资助金额:$24.23万
-
财政年份:1999
-
负责人:DAVID JOSEPH LEFER
-
依托单位:
海外基金